Ultragenyx
Commercial-stage biotechnology company developing and delivering medicines for serious rare and ultrarare genetic diseases.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 2 · Recruiting · MPS IIIA
First-in-human Study of UX016 in GNEMPhase 1 · Recruiting · GNE Myopathy
Mucopolysaccharidosis VII Disease Monitoring ProgramNA · Recruiting · Mucopolysaccharidosis VII
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring ProgramNA · Recruiting · Glycogen Storage Disease Type Ia
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis ImperfectaPhase 3 · Active Not Recruiting · Osteogenesis Imperfecta
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Phase 3 · Active Not Recruiting · Angelman Syndrome
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/ultragenyx/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.